Protoporphyrin IX is a dual inhibitor of p53/MDM2 and p53/MDM4 interactions and induces apoptosis in B-cell chronic lymphocytic leukemia cells

被引:23
|
作者
Jiang, Liren [1 ,2 ,3 ]
Malik, Natasha [1 ]
Acedo, Pilar [1 ]
Zawacka-Pankau, Joanna [1 ]
机构
[1] Karolinska Inst, Dept Microbiol Tumor & Cell Biol, Solnavagen 9, S-17165 Stockholm, Sweden
[2] Uppsala Univ, Med Fac, Dept Immunol Genet & Pathol, Box 25675105, Uppsala, Sweden
[3] Shanghai Jiao Tong Univ, Shanghai Gen Hosp, Dept Pathol Ctr, Sch Med, 100 Haining Rd, Shanghai 200080, Peoples R China
关键词
CANCER-CELLS; MUTANT P53; TRANSCRIPTION FACTOR; WILD-TYPE; AMG; 232; MDM2; PROTEIN; CHEMOTHERAPY; REACTIVATION; ACTIVATION;
D O I
10.1038/s41420-019-0157-7
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
p53 is a tumor suppressor, which belongs to the p53 family of proteins. The family consists of p53, p63 and p73 proteins, which share similar structure and function. Activation of wild-type p53 or TAp73 in tumors leads to tumor regression, and small molecules restoring the p53 pathway are in clinical development. Protoporphyrin IX (PpIX), a metabolite of aminolevulinic acid, is a clinically approved drug applied in photodynamic diagnosis and therapy. PpIX induces p53-dependent and TAp73-dependent apoptosis and inhibits TAp73/MDM2 and TAp73/MDM4 interactions. Here we demonstrate that PpIX is a dual inhibitor of p53/MDM2 and p53/MDM4 interactions and activates apoptosis in B-cell chronic lymphocytic leukemia cells without illumination and without affecting normal cells. PpIX stabilizes p53 and TAp73 proteins, induces p53-downstream apoptotic targets and provokes cancer cell death at doses non-toxic to normal cells. Our findings open up new opportunities for repurposing PpIX for treating lymphoblastic leukemia with wild-type TP53.
引用
下载
收藏
页数:11
相关论文
共 50 条
  • [11] Mdm2 and Mdm4 loss regulates distinct p53 activities
    Barboza, Juan A.
    Iwakuma, Tomoo
    Terzian, Tamara
    El-Naggar, Adel K.
    Lozano, Guillermina
    MOLECULAR CANCER RESEARCH, 2008, 6 (06) : 947 - 954
  • [12] MDM2 antagonists activate p53 and synergize with genotoxic drugs in B-cell chronic lymphocytic leukemia cells
    Coll-Mulet, Llorenc
    Iglesias-Serret, Daniel
    Santidrian, Antonio F.
    Cosialls, Ana M.
    de Frias, Merce
    Castano, Esther
    Campas, Clara
    Barragan, Montserrat
    Fernandez de Sevilla, Alberto
    Domingo, Alicia
    Vassilev, Lyubomir T.
    Pons, Gabriel
    Gil, Joan
    BLOOD, 2006, 107 (10) : 4109 - 4114
  • [13] The loss of mdm2 induces p53 mediated apoptosis
    de Rozieres, S
    Maya, R
    Oren, M
    Lozano, G
    ONCOGENE, 2000, 19 (13) : 1691 - 1697
  • [14] The loss of mdm2 induces p53 mediated apoptosis
    Sohela de Rozieres
    Ruth Maya
    Moshe Oren
    Guillermina Lozano
    Oncogene, 2000, 19 : 1691 - 1697
  • [15] Simultaneous measurement of p53:Mdm2 and p53:Mdm4 protein-protein interactions in whole cells using fluorescence labelled foci
    Frosi, Y.
    Inoue, K.
    Ramlan, Siti Radhiah
    Lane, D. P.
    Watanabe, T.
    Brown, C. J.
    SCIENTIFIC REPORTS, 2019, 9 (1)
  • [16] Binding of an inhibitor of the p53/MDM2 interaction to MDM2
    Duncan, SJ
    Cooper, MA
    Williams, DH
    CHEMICAL COMMUNICATIONS, 2003, (03) : 316 - 317
  • [17] Simultaneous measurement of p53:Mdm2 and p53:Mdm4 protein-protein interactions in whole cells using fluorescence labelled foci
    Y. Frosi
    K. Inoue
    Siti Radhiah Ramlan
    D. P. Lane
    T. Watanabe
    C. J. Brown
    Scientific Reports, 9
  • [18] Inorganic arsenic induces MDM2, p53, and their phosphorylation and affects the MDM2/p53 complex in vitro
    Yin, Jinyao
    Zhou, Qian
    Tan, Jingwen
    Che, Wangjun
    He, Yuefeng
    ENVIRONMENTAL SCIENCE AND POLLUTION RESEARCH, 2022, 29 (58) : 88078 - 88088
  • [19] Peptides and peptidomimetics in the p53/MDM2/MDM4 circuitry - a patent review
    Teveroni, Emanuela
    Luca, Rossella
    Pellegrino, Marsha
    Ciolli, Germana
    Pontecorvi, Alfredo
    Moretti, Fabiola
    EXPERT OPINION ON THERAPEUTIC PATENTS, 2016, 26 (12) : 1417 - 1429
  • [20] Tissue-specific differences of p53 inhibition by Mdm2 and Mdm4
    Grier, JD
    Xiong, SB
    Elizondo-Fraire, AC
    Parant, JM
    Lozano, G
    MOLECULAR AND CELLULAR BIOLOGY, 2006, 26 (01) : 192 - 198